Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spon... द्वारा Xenofon Baraliakos, Denis Poddubnyy, Ludwig Hammel, Marvin Heyne, Justyna Veit, Claudia Jentzsch

पूर्ण पाठ प्राप्त करें